Beam Therapeutics Inc. (NASDAQ:BEAM) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 1:30 PM EDT
Company Participants
John Evans – CEO & Director
Giuseppe Ciaramella – President
Conference Call Participants
Yanan Zhu – Wells Fargo Securities, LLC, Research Division
Presentation
Yanan Zhu
Senior Equity Analyst
Thanks, everyone, for being here. My name is Yanan Zhu. I’m one of the biotech analysts here at Wells Fargo. It is my great pleasure to introduce our next fireside chat. We are privileged to have the Beam Therapeutics team with us. And here on stage are John Evans, CEO; and Pino Ciaramella, President of the company. Thank you, Pino, and thank you, John, for being here.
John Evans
CEO & Director
Thanks for having us.
Question-and-Answer Session
Yanan Zhu
Wells Fargo Securities, LLC, Research Division
Great. So I was wondering if you could start off by providing an overview of the company and any upcoming catalysts that investors should keep in mind?
John Evans
CEO & Director
Sure. So Beam Therapeutics is a next-generation gene editing company. We use an important form of CRISPR called base editing, in which we use the same precision targeting ability of CRISPR to edit any spot in the genome, but we’ve modified the system so that it doesn’t make double-stranded breaks where you lose control of the sequence. Instead, we’re making precise single base changes at the target site.
So much more precise and much more predictability in terms of the therapeutic outcome that you’re going to have, all for a durable onetime therapy for very serious diseases. We’re applying this very broadly, but probably our core franchises are in 2 areas. One is hematology. So this is where we take the blood cells, we edit them directly to try to cure disease, lead programs in sickle cell disease.
Read the full article here